Evidence map›Paper›PMID 29904332›Full record

ReviewMetabolomics : Official journal of the Metabolomic Society2018

Citrate usage in the leading causes of blindness: new possibilities for the old metabolite.

Marta Michalczuk, Beata Urban, Tadeusz Porowski, Anna Wasilewska, Alina Bakunowicz-Łazarczyk

Open access · hybridAbstract readReview
In one paragraph

Review in Metabolomics : Official journal of the Metabolomic Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marta MichalczukDepartment of Paediatric Ophthalmology and Strabismus, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland. martaa.michalczuk@gmail.com.ORCID http://orcid.org/0000-0003-2735-4012
Beata UrbanDepartment of Paediatric Ophthalmology and Strabismus, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland.ORCID http://orcid.org/0000-0001-7100-3362
Tadeusz PorowskiDepartment of Pediatrics and Nephrology, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland.
Anna WasilewskaDepartment of Pediatrics and Nephrology, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland.ORCID http://orcid.org/0000-0003-0257-4422
Alina Bakunowicz-ŁazarczykDepartment of Paediatric Ophthalmology and Strabismus, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCitrate is an old metabolite which is best known for the role in the Krebs cycle. Citrate is widely used in many branches of medicine. In ophthalmology citrate is considered as a therapeutic agent and an useful diagnostic tool-biomarker.

objectivesTo summarize the published literature on citrate usage in the leading causes of blindness and highlight the new possibilities for this old metabolite.

methodsWe conducted a systematic search of the scientific literature about citrate usage in ophthalmology up to January 2018. The reference lists of identified articles were searched for providing in-depth information.

resultsThis systematic review included 30 articles. The role of citrate in the leading causes of blindness is presented.

conclusionsCitrate might help inhibit cataract progression, in case of questions confirm glaucoma diagnosis or improve cornea repair treatment as adjuvant agent (therapy of ulcerating cornea after alkali injury, crosslinking procedure). However, the knowledge about possible citrate usage in ophthalmology is not widely known. Promoting recent scientific knowledge about citrate usage in ophthalmology may not only benefit of medical improvement but may also limit economic costs caused by leading causes of blindness. Further studies on citrate usage in ophthalmology should continuously be the field of scientific interest.

Indexed as

BiomarkerCitrateOphthalmologyTreatment

Identifiers

PMID29904332
PMCPMC5988790
OpenAlexW2807189720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.